Table 2.
The diagnostic value of different models for detecting ESCC
| Panels | Stage | AUC (95% CI) | Se (%) | Sp (%) | Accuracy (%) | PPV (%) | NPV (%) | PLR | NLR |
|---|---|---|---|---|---|---|---|---|---|
| Four TAAbs (p53, HCCR, C‐myc, and MDM2) | All stage | 0.80 (0.75,0.85) | 49.60 | 90.40 | 71.60 | 73.28 | 70.15 | 3.38 | 0.44 |
| TNM0‐I | 0.83 (0.76,0.89) | 55.56 | 90.40 | 74.30 | 55.71 | 40.17 | 4.89 | 0.35 | |
| Tis‐T1 | 0.83 (0.77,0.90) | 58.00 | 90.40 | 74.86 | 54.41 | 40.52 | 5.00 | 0.37 | |
| N negative | 0.82 (0.76,0.88) | 53.49 | 90.40 | 73.46 | 66.30 | 38.52 | 3.83 | 0.40 | |
| Three miRNAs(miR‐21, miR‐100, and miR‐375) | All stage | 0.86 (0.82,0.91) | 60.80 | 90.40 | 77.20 | 85.42 | 72.08 | 5.20 | 0.20 |
| TNM0‐I | 0.94 (0.91,0.97) | 75.93 | 90.40 | 84.92 | 74.55 | 44.58 | 6.02 | 0.04 | |
| Tis‐T1 | 0.91 (0.86,0.96) | 68.00 | 90.40 | 83.43 | 71.43 | 44.22 | 5.75 | 0.10 | |
| N negative | 0.89 (0.85,0.94) | 65.12 | 90.40 | 80.09 | 80.56 | 42.04 | 5.30 | 0.18 | |
| 3TAAbs + 3miRNAs (HCCR, C‐myc, MDM2 miR‐21, miR‐223, and miR‐375) | All stage | 0.89 (0.85,0.93) | 68.80 | 90.40 | 80.80 | 83.48 | 78.52 | 3.85 | 0.21 |
| TNM0‐I | 0.94 (0.90,0.98) | 83.33 | 90.40 | 86.59 | 72.06 | 44.92 | 14.96 | 0.17 | |
| Tis‐T1 | 0.91 (0.86,0.96) | 80.00 | 90.40 | 84.57 | 68.85 | 44.35 | 14.29 | 0.21 | |
| N negative | 0.92 (0.88,0.96) | 75.58 | 90.40 | 83.89 | 78.89 | 43.09 | 7.16 | 0.22 |
Abbreviations: AUC, area under the receiver operating characteristic curve; CI, confidence interval; miRNAs, microRNAs; N negative: negative lymph node metastasis; NLR, negative likelihood ratio; NPV, negative predictive value; PLV, positive likelihood value; PPV, positive predictive value; Se, sensitivity; Sp, specificity; TAAb, autoantibodies against tumor‐associated antigens.